Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.06 USD | +0.27% | +2.64% | -12.18% |
10/05 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
10/05 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.18% | 91.34B | |
+29.98% | 682B | |
+31.67% | 586B | |
-3.52% | 364B | |
+18.59% | 327B | |
+4.07% | 285B | |
+16.43% | 240B | |
+9.36% | 209B | |
-9.08% | 203B | |
+7.09% | 165B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers Squibb Says Opdivo-chemotherapy Combination Gets FDA Nod to Treat Non-small Cell Lung Cancer